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Activating mutations of RAS frequently occur in sub-
sets of human cancers, indicating that RAS activation
is important for tumorigenesis. However, a large pro-
portion of these cancers still retain wild-type RAS
alleles, suggesting that either the RAS pathway is ac-
tivated in a distinct manner or another pathway is de-
regulated. To uncover novel tumor-suppressor genes,
we screened an RNA-interference library for knock-
down constructs that transform human primary cells
in the absence of ectopically introduced oncogenic
RAS. Here we report the identification of PITX1,
whose inhibition induces the RAS pathway and tu-
morigenicity. Interestingly, we observed low expres-
sion of PITX1 in prostate and bladder tumors and in
colon cancer cell lines containing wild-type RAS. Res-
toration of PITX1 in the colon cancer cells inhibited
tumorigenicity in a wild-type RAS-dependent manner.
Finally, we identified RASAL1, a RAS-GTPase-acti-
vating protein, as a transcription target through
which PITX1 affects RAS function. Thus, PITX1 sup-
presses tumorigenicity by downregulating the RAS
pathway through RASAL1.
Introduction
Human tumors harbor multiple genetic alterations in
genes controlling cell growth, differentiation, and sur-
vival. These genetic changes comprise activation of on-
cogenes and inactivation of tumor-suppressor genes.
Frequently, the p53 and pRb tumor-suppressor genes
as well as the RAS oncogenes are mutated, or compo-
nents of their pathways are altered (Hanahan and Wein-
berg, 2000). Delineation of the essential alterations dur-
ing tumorigenesis became feasible by the development
of an in vitro system for neoplastic transformation of
human primary cells (Hahn et al., 1999; Hahn and Wein-
berg, 2002). Through the use of ectopic expression of
viral and mutant human genes, homologous recombi-
nation, and recently also short-hairpin RNA (shRNA)
vectors, it became apparent that telomerase, the pRb,
p53, PI3K, and the RAS pathways must be altered to
allow transformation (Hahn et al., 1999; Voorhoeve and
Agami, 2003; Zhao et al., 2003). Recently, we described*Correspondence: r.agami@nki.nla transformation model that allows anchorage-inde-
pendent growth of human primary BJ fibroblast cells by
overexpression of the catalytic subunit of telomerase
(hTERT), oncogenic H-RASV12, and SV40 small t antigen
(st) in combination with the inhibition of the expression
of p53 and p16INK4A using shRNA vectors (Figure 1A;
Voorhoeve and Agami, 2003). In this model, oncogenic
RAS expression was indispensable, as the omission of
RASV12 resulted in very few transformed cells (Figure
1A, Tr(-onc) cells).
The RAS gene family is one of the most frequently
activated oncogenes in human cancer (Bos, 1989). RAS
proteins are small monomeric GTPases of 21 kDa that
play a key role in transducing growth signals from cell-
surface receptors to the nucleus. Activating point mu-
tations in RAS, which are found in tumors originating
from colon, lung, pancreas, and other tissues, promote
cellular transformation by growth-factor-independent
stimulation of cell proliferation and cell survival. In hu-
mans, at least four RAS genes have been identified,
H-RAS, N-RAS, R-RAS, and K-RAS, which bear high
sequence conservation. Like other GTPases, RAS acts
as a molecular switch that oscillates between an active
GTP bound and an inactive GDP bound form. The activ-
ity of RAS is tightly regulated by two opposing compo-
nents: GTP-exchange factors (GEFs) that induce disso-
ciation of GDP, which allows binding of GTP, and
GTPase-activating proteins (GAPs) that trigger the hy-
drolysis of bound GTP and attenuate RAS activity (Re-
pasky et al., 2004; Wolthuis and Bos, 1999). The impor-
tance of GAPs in RAS inactivation has been established
by the predisposition to tumor development of humans
with mutations in the RAS-GAP gene NF1 (Arun and
Gutmann, 2004; Harrisingh and Lloyd, 2004). Here we
used in vitro neoplastic transformation assays in com-
bination with an RNA interference (RNAi) library to
screen for novel tumor-suppressor genes, whose inhi-
bition substitutes for the activity of oncogenic RAS.
Results and Discussion
Inhibition of PITX1 Expression Induces Oncogenic
Signals in Human Primary Cells
We retrovirally transduced Tr(-onc) cells with half of the
RNAi library (40 pools that contain RNAi constructs de-
signed to target 4000 genes) (Berns et al., 2004) and
screened for colonies growing in soft agar (Figure 1A).
Several colonies emerged in a couple of the pools,
whereas most of the pools showed no activity (Figure
1B). As expected, very efficient transformation was ob-
served when Tr(-onc) cells were transduced with RASV12,
either undiluted or diluted to 1:250 with control vector.
We subsequently picked and expanded the colonies,
PCR amplified their shRNA inserts, and subcloned
them into a retroviral shRNA vector (pRS) for sequence
identification and functional validation (Figure 1C).
Using this approach, we identified knockdown (kd) con-
structs targeting the Kru¨ppel-like transcription factor
KLF4, the proapoptotic calcium binding protein PDCD6
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850Figure 1. The Identification of PITX1 in a Genetic Screen for Novel Tumor-Suppressor Genes
(A) A scheme showing a protocol for screening for tumorigenic conversion of primary human cells. Pr represents primary cells, Tr represents
transformed cells, and st is the SV40 small t antigen. Tr(-onc) are primary human BJ cells that contain ectopic expression of hTERT, st, and
the p53 and p16INK4A knockdown constructs. Tr(-onc) cells were infected with pools of the NKI RNAi library, and the ability of cells to grow in
soft agar was tested.
(B) A histogram summarizing the number of colonies observed per individual pool.
(C) A scheme to show the identification procedure. Colonies growing in the soft agar assay were picked and expanded, and their integrated
shRNA inserts (typically 3–8 per colony) were PCR amplified and subcloned into a new retroviral vector for sequencing and verification
of activity.
(D) A representative picture of a soft agar assay with Tr(-onc) cells transduced with control vector and PITX1kd, PDCD6kd, KLF4kd, and RASV12
overexpression. For clarity, colonies were imaged with light and fluorescence microscopy, as they contain the small-t-GFP expression vector.
(E) MCF-7 cells were electroporated with constructs encoding for PITX1-GFP and H2B-GFP together with either pRS-PITX1kd or a control
vector. Whole-cell extracts (WCE) were made and immunoblotted with anti-GFP antisera.
(F) Tr(-onc) cells were transduced with pRS-PITX1kd or vector control and drug selected with blasticidin for 4 days. Total RNA was extracted
and subjected to semiquantitative RT-PCR analysis. Aliquots were taken at the indicated cycles, separated on a 2% agarose gel, and stained
with EtBr.
(G) T47D and SKBr3 cells were electroporated with pRS-PITX1kd or control construct (w90% transfection efficiencies). Forty-eight hours after
transfection, WCE were produced, separated on 10% SDS-PAGE, and immunoblotted with an anti-PITX1 antiserum.
(H) Two additional active pRS-PITX1kd retroviral vectors 2 and 3 (columns 2 and 3) were transduced into Tr(-onc) cells, drug selected for 7
days, and tested for colonigenic growth in soft agar. As controls, a control vector and a RASV12-expressing vector were included. The number
of colonies that appeared per 2 × 104 cells is shown. This experiment was reproduced twice.(ALG-2), and the homeodomain pituitary transcription
tfactor PITX1, with a transforming activity comparable
to RASV12 overexpression (Figure 1D). Interestingly, i
eKLF4 was shown to exhibit putative tumor-suppressive
functions in humans (Dang et al., 2003; Ohnishi et al., p
P2003; Zhao et al., 2004), whereas PDCD6 has recently
been shown to be downregulated in ocular melanoma u
w(Subramanian et al., 2004). As little is known about pos-
sible tumor-inhibitory roles of PITX1, we focused here T
on PITX1.To study the possible involvement of PITX1 in con-
rolling oncogenic pathways, we first assessed the abil-
ty of the PITX1kd construct to suppress PITX1 gene
xpression. In transient transfections, PITX1kd showed
otent inhibition of the expression of cotransfected
ITX1-GFP, while the expression of H2B-GFP remained
nchanged (Figure 1E). By semiquantitative RT-PCR,
e found detectable levels of PITX1 mRNA in the
r(-onc) cells that were reduced 8- to 10-fold in the
Tr(-onc)/PITX1kd cells (Figure 1F). We also scanned sev-
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found clear PITX1 (39 kDa) expression in SKBr3 and
T47D cells (Figure 1G). Transfection of these cells with
pRS-PITX1kd resulted in a marked reduction in PITX1
protein levels, indicating that our PITX1kd vector is a
potent inhibitor of PITX1. Finally, to rule out possible
off-target effects of the PITX1kd construct and address
the role of the PITX1 gene in cellular transformation, we
generated two additional active PITX1kd vectors. These
vectors were introduced into Tr(-onc) cells, examined in
the soft agar assay, and found to possess activity sim-
ilar to that of the original PITX1kd construct (Figure 1H).
Thus, the specific inhibition of PITX1 expression in-
duces oncogenic signals in human primary cells.
Suppression of PITX1 Expression Activates
the RAS Pathway
Our results thus far may imply that RAS is activated
when PITX1 expression is inhibited. To examine this hy-
pothesis, we first monitored the RAS status using the
property of the RAS binding domain of RAF (RAF-RBD),
which associates exclusively with activated RAS (Fig-
ure 2A). We transduced Tr(-onc) cells with RASV12,
PITX1kd, or control vectors and first analyzed RAS
levels by Western blot using an anti-pan-RAS antibody.
There was no significant difference in the total amount
of endogenous RAS expressed in control and PITX1kd
cells, and there were higher levels of RAS in the
RASV12-transduced cells (Figure 2B). When the same
lysates were used for a pull-down experiment with GST-
RAF-RBD, a relatively high amount of active RAS was
detected in PITX1kd cells and, as expected, in the
RASV12-overexpressing cells (Figure 2B). Subsequently,
we assayed extracts for phosphorylated ERK, which is
a downstream target of RAS (Robinson and Cobb,Figure 2. Suppression of PITX1 Expression
Activates the RAS Pathway
(A) A schematic drawing showing the selec-
tive binding of the RAF-RAS binding domain
(RAF-RBD) to activated RAS.
(B) Tr(-onc) cells were transduced with the in-
dicated vectors. WCE were made and used
for pull-down assays using RAF-RBD. Ly-
sates were separated on a 12% SDS-PAGE
gel and immunoblotted with a pan-RAS an-
tibody.
(C and D) WCE from similar populations as
used in (B) were made, separated on a 10%
SDS-PAGE gel, and immunoblotted with the
indicated antibodies.1997). Clearly, higher levels of phospho-ERK were ob-served in the PITX1kd cells and the RASV12-overex-
pressing cells when compared to control cells (Figure
2C). Control immunostaining for total ERK2 and CDK4
showed no such difference. Finally, we determined the
expression levels of cyclin D1, another target of
RASV12. In accordance with the results above, both
PITX1kd and RASV12 induced higher levels of cyclin D1
than the vector control (Figure 2D), showing that sup-
pression of PITX1 expression activates the RAS pathway.
Comparable Phenotypes Are Induced by Oncogenic
RAS and PITX1kd in Human Cells
Primary human cells possess protective mechanisms
that oppose the sustained induction of RAS by activa-
ting the p53 and p16INK4A growth-inhibitory pathways
(Serrano et al., 1997; Figure 3A). To test whether the
suppression of PITX1 expression causes the same phe-
notype as RASV12 overexpression, we monitored the
proliferation rates of BJ/hTERT and BJ/hTERT/p53kd/
p16kd cells that were transduced with either PITX1kd,
RASV12, or the vector control. We found that both
PITX1kd and RASV12 induce a growth arrest in a p53-
and p16INK4A-dependent manner (Figure 3B). The
growth arrest imposed by sustained RASV12 activity is
irreversible and termed premature senescence (Serrano
et al., 1997). Two of the most commonly used markers
for senescence are the appearance of a flat cell mor-
phology and the expression of acidic β-gal (Dimri et al.,
1995). Accordingly, high numbers of cells with flat mor-
phology and positive β-gal staining were observed in
BJ/hTERT cells overexpressing RASV12 but not in the
BJ/hTERT/p53kd/p16kd cells. An apparently similar phe-
notype was observed when PITX1 expression was sup-
pressed (Figures 3C and 3D). Furthermore, only when
the p53-p16INK4A protective mechanisms were elimi-
nated by suppressing their expression were cellular
Cell
852Figure 3. Oncogenic RAS and PITX1kd Induce Comparable Phenotypes in Human Cells
(A) A schematic model showing the p53/p16INK4A-dependent growth arrest (premature senescent phenotype) induced by oncogenic RAS.
(B) BJ/hTERT or BJ/hTERT/p53kd/p16kd cells were transduced with RASV12 expression vector, PITX1kd, and a control vector. Cells were drug
selected for 3–4 days, and subsequently the number of cells was monitored in time in each culture. This experiment was reproduced
three times.
(C) The same cell populations described in (B) were plated on a 2.5 cm dish and stained 48 hr later for acidic β-gal expression. Positive cells
are stained blue. This experiment was reproduced twice.
(D) Quantification of the experiment presented in (C). Arbitrary fields were chosen and the percentage of β-gal-positive cells was determined.
The bars represent the mean percentage of β-gal-positive cells ± SD of three arbitrary fields in two independent experiments.
(E) The indicated genetically modified primary BJ/hTERT cells were transduced with PITX1kd, RASV12, and vector control; selected; and plated
in soft agar. The number of colonies per 2 × 104 cells is shown. This experiment was reproduced twice in duplicates.growth and transformation efficiently induced by either r
Soverexpression of RASV12 or PITX1 inhibition (Figure 3E;
Voorhoeve and Agami, 2003). Thus, the inhibition of c
pPITX1 induces proliferation signals that phenotypically
mimic oncogenic activation of the RAS pathway. t
p
pPITX1 Expression Patterns in Human Cancer
iTo obtain support for PITX1 involvement in human can-
Acer, we scanned the gene-expression database On-
tcomine for differential PITX1 expression patterns in
cnormal versus tumor tissue of different sources. We
pfound PITX1 expression to be altered in prostate and
dbladder cancers relative to their normal tissue (Table1). In both cases, PITX1 expression was significantly for prostate cancer.
Table 1. Lower Expression of PITX1 in Prostate and Bladder Cancers Compared with Normal Tissues
Tissue Type Number of Samples Mean p Value Study
Normal-tissue prostate 50 −0.437
Prostate tumor 52 −0.931 2.6e
−4 Singh et al., 2002
Normal-tissue bladder 18 0.206
Bladder cell carcinoma 11 −1.624 4.2e
−4 Ramaswamy et al., 2001
Several gene-expression studies comparing normal and cancer tissues were scanned for PITX1 using Oncomine software (http://141.214.6.50/
oncomine/main/index.jsp). Data from two studies (Ramaswamy et al., 2
are shown.educed in the tumor material (Ramaswamy et al., 2001;
ingh et al., 2002). Of particular interest was the highly
ancer-prone prostate tissue in which PITX1 is well ex-
ressed (Figure S1). To directly test whether the reduc-
ion in PITX1 levels also induces transformation in a
rimary human prostate model system, we obtained the
rimary-derived human prostate RWPE-1 cells (contain-
ng HPV and readily transformed by oncogenic K-RAS,
TCC). In soft agar assays, we found that the transduc-
ion of RWPE-1 cells with the PITX1kd, but not with a
ontrol vector, induces very efficient anchorage-inde-
endent growth (Figure 4A). This result provides evi-
ence that PITX1 is likely a relevant tumor suppressor001; Singh et al., 2002) comparing prostate and bladder tissues
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(A) RWPE-1 human prostate cells containing human papilloma viral sequences (CRL-11609, ATCC) were transduced with either a control or
a PITX1kd vector and tested for colony growth in soft agar. A representative picture of the plates and a histogram of the number of colonies
per plate are shown. This experiment was reproduced twice.
(B) WCE from Tr(-onc) cells and several colon cancer cell lines were subjected to pull-down experiments with the active RAS binding domain
of RAF (GST-RAF-RBD), separated on 12% SDS-PAGE, and immunoblotted to detect RAS. Cell lines known to possess no mutations in RAS
alleles are marked green. For comparison, the amount of total RAS in WCE is shown. BG is a background band for loading control.
(C) RT-PCR of RNA isolated from the indicated colon cancer cell lines. The RAS status of these cell lines is indicated, and cell lines with only
wild-type RAS alleles are marked green. As a control, we used an RT-PCR for ALG-2 that showed similar expression levels between the
cell lines.
(D) WCE (30 g) from the indicated tumor cell lines were separated on 10% SDS-PAGE and examined with an anti-PITX1 antiserum. Cell lines
with only wild-type RAS alleles are marked green. The 39 kDa PITX1 band is indicated.
(E) Extracts from stably transduced control, PITX1kd, and RASV12 Tr(-onc) cells were separated on SDS-PAGE and immunoblotted to detect
PITX1, RAS, and the control CDK4 proteins.A Causal Relationship between PITX1 Levels
and Wild-Type RAS in Colon Cancer
Although activating RAS mutations are frequently found
in subsets of human cancers, other tumors in these
panels contain no RAS mutations. For example, only
50% of all colon tumors, 30% of lung cancer, and 5%
of prostate cancer in the United States are estimated
to contain oncogenic RAS mutation (Bos, 1989; Rhim,
2001). We therefore initially asked whether cancer cell
lines with wild-type RAS genotypes exhibit enhanced
RAS activity. We used pull-down experiments with GST-
RAF-RBD to compare RAS activity between the pri-
mary-derived Tr(-onc) cells and several colon cancer cell
lines (Figure 4B, cell lines with wt RAS alleles are
marked with green ). Regardless of the RAS status, high
levels of RAS activity were observed in all the cancer
cell lines tested. In contrast, no correlation was seen
between the protein levels of RAS and its activity in the
different cell extracts we used.To investigate whether PITX1 contributes to the en-
hanced activity of endogenous wt RAS, we examinedPITX1 expression in the colon cancer cells. First, using
semiquantitative RT-PCR, we found that several colon
cancer cell lines express very low levels of PITX1
mRNA (Figure 4C). Significantly, the low levels of PITX1
expression correlated with the presence of wild-type
RAS alleles (marked green). This correlation was veri-
fied by immunoblot analysis with PITX1 antiserum (Fig-
ure 4D). These results can be explained by either the
fact that loss of PITX1 precludes the requirement to
mutate RAS or the fact that PITX1 expression is re-
pressed by oncogenic RAS. As overexpression of
RASV12 in Tr(-onc) or HEK293 cells did not result in ele-
vated levels of PITX1 protein or activity, respectively
(Figure 4E and Figure S2), our data demonstrate a
causal relationship between reduced PITX1 levels and
wild-type RAS.
PITX1 Inhibits Growth and Tumorigenicity
in a Wild-Type-RAS-Dependent Manner
The correlation between wild-type RAS expression and
low PITX1 levels in colon cancer cell lines suggests that
Cell
854PITX1 restrains endogenous wt RAS activity. To test I
Pwhether such a functional interaction exists, we con-
structed a retroviral vector containing PITX1-GFP and w
lchecked its activity. Similar to endogenous PITX1,
PITX1-GFP was localized in the nucleus and activated t
wthe well-known PITX1 target the pro-opiomelanocortin
(POMC) promoter (Lamonerie et al., 1996; Figures 5A c
and 5B). We then transiently transfected HeLa cells
with PITX1-GFP, control H2B-GFP, and RASV12 vectors t
Pand examined the RAS pathway by immunoblot analy-
sis. We observed high levels of phosphorylated ERK in v
ccontrol-transfected HeLa cells, which were not signifi-
cantly elevated when RASV12 was introduced (Figure a
I5C). This result is different from the BJ primary cells
(Figure 2C), most likely because the RAS pathway is cFigure 5. PITX1 Inhibits Growth and Tumorigenicity in a RAS-Dependent Manner
(A) MCF-7 cells were transfected with a vector expressing the PITX1-GFP chimera protein. Cells were fixed and stained with a PITX1 antibody.
Nuclear localization of endogenous PITX1 and overexpressed PITX1-GFP can be detected in the enlarged picture.
(B) T47D cells (containing relatively high PITX1 expression, Figure S3) were transfected with POMC-promoter-firefly-luciferase and control
SV40-renilla-luciferase constructs together with either vector control, PITX1-GFP, or PITX1kd. The graph represents the mean relative firefly/
renilla activity ± SD of three experiments.
(C) HeLa cells were transfected with the indicated plasmids, and WCE were made after 48 hr, separated on 10% SDS-PAGE, and immunoblot-
ted to detect the indicated proteins.
(D) Caco-2 cells were transduced with retroviral vectors expressing PITX1-GFP or H2B-GFP control. After 3 days, cell cultures were divided
in two and transduced with either a RASV12-expressing vector or a control vector. The percentage of GFP-positive cells was determined every
4–7 days.
(E) Cells similar to those described in (D) were plated in soft agar, and the percentage of GFP-expressing colonies per dish was determined
17–21 days later. The experiments in (D) and (E) were reproduced three times.
(F) The same cell populations as in (D) were injected into the flank of nude mice. After 3 weeks of growth, the tumors were removed, cut into
small slides, and visualized by fluorescent microscopy. In parallel, cells were prepared from tumors and cultured for a week, and the percen-
tage of GFP-positive cells was determined by flow cytometry.already optimally active in the HeLa cancer cell line.n contrast, we found lower levels of phospho-ERK in
ITX1-GFP-transfected cells compared with control,
hereas the ERK2 levels remain unchanged (Figure 5C,
anes 1 and 3). Interestingly, this effect was negated by
he cotransfection of RASV12 (lanes 2 and 4). Together
ith the results presented in Figure 2, these data indi-
ate that PITX1 negatively regulates the RAS pathway.
Consequently, we tested whether the wt-RAS-con-
aining cancer cell lines depended on the reduced
ITX1 expression for their transformed phenotype. We
irally transduced the low-PITX1-expressing Caco-2
ells with either PITX1-GFP or H2B-GFP control vectors
nd obtained 20%–30% GFP-positive cells (Figure 5D).
mportantly, the level of PITX1-GFP in the transduced
ells was comparable to the level in cells endogenouslyexpressing PITX1 (Figure S3). Subsequently, each cell
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tor control, and both the growth capacity and the tu-
morigenic potential of these cells were monitored. Fig-
ures 5D and 5E show that the expression of PITX1-GFP
inhibits cellular proliferation and tumorigenicity in cells
with low PITX1 levels. Remarkably, in both cases, the
introduction of oncogenic RASV12 rescued the PITX1-
mediated effects almost completely, whereas no signifi-
cant change occurred in control H2B-GFP cells. Similar
results were obtained with WiDr and Colo-205 cells,
other colon cancer cell lines containing wild-type RAS
alleles and low levels of PITX1 (data not shown).
To directly address the tumor-suppressive function
of PITX1, we injected Caco-2 cells into the flank of
athymic nude mice. These cells contained a 20%–25%
subpopulation of cells with either PITX1-GFP or H2B-
GFP control, with or without RASV12. After 3 weeks, tu-
mors appeared in all mice and were isolated and ana-
lyzed by fluorescence microscopy and flow cytometry.
We found very few PITX1-GFP-containing tumor cells,
whereas the expected levels of GFP-positive cells were
observed in the tumors emerging from either PITX-GFP
with RASV12 or the H2B control cells (Figure 5F). We
therefore conclude that in colon cancer cell lines that
have low PITX1 expression and wt RAS genes, PITX1
re-expression suppresses growth and tumorigenicity in
a wt-RAS-dependent manner.
RASAL1 Mediates PITX1 Effects on RAS
Activity and Tumorigenicity
Next we addressed the mechanism through which
PITX1 regulates RAS activity. Thus far, our results indi-
cate a cell-autonomous mechanism for regulation of
RAS by PITX1 (Figures 5D–5F), suggesting a direct con-
nection between PITX1 and RAS rather than via growth
factors. RAS is activated by GTP-exchange factors
(GEFs) and inhibited by GTP-activating factors (GAPs)
(Repasky et al., 2004). As a transcriptional activator,
PITX1 might activate a RAS-GAP to inhibit RAS activity
(Figure 6A). To date, at least eight human RAS-GAP
gene members are known: RASA1–4, RASAL1 and 2,
NF1, and SYN-GAP. We therefore searched for PITX1
consensus binding sites (TAA[T/G]CC) in 2 kb upstream
promoter regions of these RAS-GAP genes and found
only RASAL1 to contain this site (Figure 6B). RASAL1
is a RAS-GAP that senses and connects Ca2+ signals
to RAS activity through synchronous oscillatory associ-
ation with the plasma membrane (Walker et al., 2004).
To test whether RASAL1 is a target of PITX1, we ex-
amined RASAL1 mRNA levels using quantitative Q-PCR.
Transient transfection of HEK293 cells with PITX1-GFP
more than doubled the endogenous RASAL1 levels
over those of the H2B-GFP control (Figure 6C). More-
over, transfection of a RASAL1kd construct reduced
RASAL1 mRNA levels by more than 70%, whereas sup-
pression of PITX1 resulted in a reduction of 40%–50%.
The later result is expected, as RASAL1kd causes an in-
stant degradation of RASAL1 mRNA, whereas PITX1kd is
expected to reduce transcription activity of RASAL1
only after a significant reduction in PITX1 protein is
achieved. To further examine the PITX1-RASAL1 con-
nection in more detail, we cloned a 1.4 kb region includ-
ing the PITX1 binding site and the predicted transcrip-tion start site of RASAL1 in front of a firefly luciferase
gene (Figure 6B). Using transient transfections in
HEK293 cells, we found this region to contain high pro-
moter activity, which was further stimulated 6-fold by
cotransfection of PITX1-GFP (Figure 6D). Dissection of
the RASAL1 promoter region revealed that PITX1 activ-
ity was correlated with the overall promoter activity and
localized around the PITX1 site. These results suggest
that PITX1 interacts directly with the RASAL1 promoter.
To test this hypothesis, we performed chromatin immu-
noprecipitation (ChIP) analysis on HEK293 cells trans-
fected with PITX1-GFP or H2B-GFP control. Figure 6E
shows that fragments of the RASAL1 promoter were
efficiently precipitated from cells transfected with PITX1-
GFP and immunoprecipitated with anti-GFP antibodies
but not from control-transfected cells or immunopre-
cipitation with a control antibody. Altogether, these re-
sults strongly suggest that RASAL1 is a transcription
target of PITX1.
Finally, we tested the genetic interaction between
PITX1, RASAL1, and the RAS pathway. As observed
above, overexpression of PITX1-GFP inhibited phos-
phorylation of ERK in a wild-type-RAS-dependent man-
ner (Figure 6F). Introduction of RASAL1kd (which results
in a more than 70% reduction in RASAL1 mRNA levels,
Figure 6C) or the controls PITX1kd and overexpression
of RASV12 negated this effect, indicating that RASAL1
is a mediator of PITX1 effects. Control immunostainings
showed similar levels of ERK2 and PITX1-GFP in those
cells. Last, to examine whether RASAL1, similarly to
PITX1, is part of a network that inhibits oncogenic
growth, we transduced Tr(-onc) cells with RASAL1kd and
selected and plated them in soft agar to test for an-
chorage-independent growth. Figure 6G shows that the
inhibition of RASAL1 expression induced tumorigenic
growth that resembled the activity of PITX1kd, indicat-
ing that RASAL1 is a mediator of RAS inhibition and
tumor suppression by PITX1. However, as the activity
of RASAL1kd was lower than that of PITX1kd (approxi-
mately half), whereas its effect on RASAL1 mRNA was
greater, it is likely that RASAL1 is not the only factor
mediating the PITX1 tumor-suppressive effects.
Conclusions
Collectively, we describe here an approach to uncover
tumor-suppressor genes that function as inhibitors of
the RAS pathway. For this purpose, we used genetically
modified primary human fibroblasts whose sole require-
ment for transformation is the deregulation of RAS ac-
tivity. This strategy is potentially also suitable for the
identification of tumor suppressors that regulate other
proteins and pathways, such as p53 and p16INK4A,
whose inhibition was defined as a requirement for this
process (Hahn et al., 1999; Voorhoeve and Agami,
2003). We demonstrate the power of this approach by
the identification of PITX1. PITX1 regulates the RAS
pathway and thereby tumorigenesis. The tumor-sup-
pressive function of PITX1 is supported by the correla-
tion between the low PITX1 levels present in colon can-
cer cell lines and wt RAS expression (Figures 4 and 5)
and the low PITX1 expression levels in prostate and
bladder tumor tissues compared with normal tissues
(Table 1). Moreover, we found in a primary-derived hu-
Cell
856Figure 6. RASAL1 Mediates PITX1 Effects on RAS Activity and Tumorigenicity
(A) A schematic model showing how PITX1 may regulate the RAS pathway through RAS-GAPs.
(B) Two kilobases of RASAL1 upstream sequences were analyzed by McPromoter, a transcription-start-site prediction program for eukaryotic
genes (http://genes.mit.edu/McPromoter.html). Nucleotides above the threshold (green line) are likely to serve as a transcription start site.
TAAGCC is the consensus DNA binding sequence of PITX1. Also shown is the RASAL1 upstream fragment used for the luciferase assays.
(C) HEK293 cells were transfected with the indicated vectors and harvested 48 hr later. RNA was extracted and used for quantitative RT-PCR
(Q-PCR) to detect RASAL1 and the control CDK4 transcripts. Intensity of bands was measured using the Tina program. The figure shows the
mean ± SD from three independent experiments.
(D) HEK293 cells were transfected with the indicated firefly luciferase constructs together with SV40-renilla luciferase and either PITX1-GFP
or the control H2B-GFP. Forty-eight hours after transfection, the ratio firefly/renilla was determined. The mean ± SD from three experiments
is shown.
(E) HEK293 cells were transfected with H2B-GFP and PITX1-GFP constructs and subjected to ChIP analysis.
(F) HeLa cells were transfected with the indicated combinations of plasmids and immunoblotted to detect the indicated proteins.
(G) Tr(-onc) cells were transduced with the indicated constructs, selected with blasticidin, and plated in soft agar. The number of colonies was
monitored 17 days later. The bars represent the mean number of colonies ± SD of three experiments.
(H) A schematic model showing the mechanism through which PITX1 restrains the wt-RAS transforming potential.man prostate cell model susceptibility to PITX1kd-medi- n
cated transformation, which provides evidence that our
transformation screen, although performed in fibro- (
wblasts, can identify relevant tumor suppressors for hu-
man cancer. f
dWe provide further genetic evidence for the regula-
tion of the RAS pathway by PITX1 through RASAL1, a w
pmember of the RAS-GAP family. Interestingly, inhibition
of RASAL1 expression potently induced tumorigenicity f
wof human primary cells, suggesting that RASAL1, on its
own, may also possess tumor-suppressive functions. c
RAnother tumor suppressor with a RAS-GAP activity isthe neurofibromin (NF1) gene. Mutations in NF1 causeeurofibromatosis type I, which is characterized by
afé-au-lait spots and fibromatous tumors of the skin
Buchberg et al., 1990). It is interesting to note that
hile the inhibition of RASAL1 activity caused a trans-
orming phenotype in our system (Figure 6G), knock-
owns of NF1 showed no activity and NF1 expression
as not altered when PITX1 expression was sup-
ressed (data not shown). Since the tumor-suppressive
unction of NF1 is restricted to certain nerve tissues,
hereas that of PITX1 is found in prostate, bladder, and
olon tissues, it is tempting to speculate that specific
AS-GAPs control RAS activity in different tissues, buttheir inhibition is a general mechanism to provoke wt-
PITX1, a Suppressor of RAS Oncogenicity
857RAS oncogenic activity and carcinogenesis. Finally, our
findings show that re-expression of PITX1 in certain
late-stage colon cancers is sufficient to alter their tu-
morigenic fate; this finding could be utilized in the fu-
ture for cancer therapy. Thus, our study opens up new




pRetroSuper (pRS)-p53kd, -p16kd, and -p14kd; pMSCV-Blast RasV12;
and pMSCV-GFP-st were described previously by Voorhoeve et al.
(Voorhoeve and Agami, 2003). pRS-Blast was created by replacing
the puromycin-resistance gene with a blasticidin-resistance gene.
LZRS-PITX1-GFP was generated by PCR amplification and cloning
of full-length PITX1 into LZRS-MS-IRES-GFP. pBabe-H2B-GFP was
generated by cloning H2B-GFP into pBabepuro. pBabepuro-hTERT
and LZRS-Neo-ecotropic receptor were described previously (Brum-
melkamp et al., 2002a; Counter et al., 1998). RASAL1 promoter lucif-
erase constructs were generated by cloning PCR-amplified RASAL1
promoter sequences into a pGL3 basic vector. For the genomic
PCR amplification, the following primers were used: construct 1,
forw1 GGCGGTACCCAGGGAGAAATAAGTGTGCGAACGGATCTGT
TCTGGG and rev1 GGCAAGCTTGAAGGGCGCTCAGGTTCCGAG
GCTGGACCAGGGGACG; construct 2, forw1 and rev2 GGCAAG
CTTGGGGGTCCGTTCAGAGTCAAGGGAGGGG; construct 3, forw2
GGCGGTACCGGGGGCGGAGAGGTGTGAATATGTTGG and rev1;
construct 4, forw3 GGCGGTACCCTGGGTTCTGTGTTTAACTGG
AAACTAG and rev1. Construct 5 was generated after removing a
50 bp fragment (ApaI digestion) out of construct 4, and construct
6 was generated after digestion of construct 4 with SacI and HindIII
and religation into pGL3 basic.
The construction of the NKI RNAi library has been described pre-
viously (Berns et al., 2004). Additional information about the library
can be found at http://screeninc.nki.nl. The constructs pRS-Blast-
PITX1 2 and 3 were designed as previously described (Brummel-
kamp et al., 2002b) to target PITX1 at positions 591 and 924 base
pairs after the start codon, respectively. pRS-Blast-RASAL1 targets
RASAL1 at a position 519 base pairs after the start codon.
Antibodies against p-ERK (E-4), CDK4 (C-22), and cyclin D1 (M-20)
were purchased from Santa Cruz; the antibody against pan-RAS
was from Transduction Laboratories. The rabbit PITX1 antiserum
was raised against a unique PITX1 peptide, CGYGALQGPASGL
NACQYNS.
Mice, Cell Culture, Transfection, and Retroviral Transduction
In order to obtain Caco-2-derived tumors, 1 × 106 cells were in-
jected subcutaneously in the flank of athymic nude mice. After
three weeks of growth, the tumors were removed, dissected into
small slides, visualized by fluorescence microscopy, and analyzed
by flow cytometry.
All cell lines described here, except for RWPE-1, were cultured
in DMEM supplemented with 10% heat-inactivated fetal calf serum.
RWPE-1 cells were cultured in keratinocyte-free medium supple-
mented with 5 ng/ml human recombinant EGF and 0.05 mg/ml bo-
vine pituitary extract. T47D, MCF-7, Skbr3, HeLa, and Caco-2 cells
were transfected by electroporation as described previously
(Agami and Bernards, 2000). Ecopack2, HEK293, and phoenix cells
were transiently transfected using the calcium phosphate precipi-
tation technique. The generation of BJ-ET-st p53kd, p16kd cells was
described before by Voorhoeve et al. (Voorhoeve and Agami, 2003).
BJ cells were infected with amphotropic retrovirus carrying an ex-
pression cassette for the ecotropic receptor (Brummelkamp et al.,
2002a) and selected with 500 g/ml G418. After selection, the cells
were transduced with ecotropic retroviral supernatants in the pres-
ence of 8 g/ml polybrene and selected with either 400 g/ml hy-
gromycin B, 5 g/ml blasticidin or 1 g/ml puromycin. Caco-2 and
RWPE-1 cells expressing an ecotropic receptor were generated by
an amphotropic-retrovirus transduction.
Recovery of shRNA Inserts
Genomic DNA from expanded colonies was isolated by incubating
the cells O/N at 42°C in a proteinase K solution (0.04% prot K, Tris-HCl [pH 8.0], 1 mM EDTA, 1% Tween). After heat denaturing the
proteinase K, the shRNA inserts were PCR amplified using the pRS
forw CCCTTGAACCTCCTCGTTCGACC and pRS rev GAGGCGC
ACCGTGGGCTTGTACTCGGTCAT primers. The PCR-amplified prod-
ucts were recloned into pRS-Blast and sequenced with Big-dye
terminator (Perkin Elmer) using pRS-seq primer GCTGACGTCAT
CAACCCGCT.
Soft Agar Assay
Cells were resuspended in DMEM containing 0.4% low-melting
agarose (Sigma, type VII) and 10% FCS and seeded onto a coating
of 1% low-melting agarose in DMEM containing 10% FCS. After 3
weeks of growth, the number of colonies was scored and, if appli-
cable, picked for further analysis.
Proliferation Assay and -Gal Staining
BJ/hTERT and BJ/hTERT/p53kd/p16kd cells were transduced with
either MSCV-Rasv12, MSCV-Blast, or pRS-PITX1kd. Cells were se-
lected for 4 days with 5 g/ml blasticidin, and 6 × 104 cells were
seeded in a 2.5 cm plate. Cells were counted and split every 3.5
days.
Two weeks after selection, cells were stained with X-gal. The
cells were fixed with a 2% formaldehyde/0.2% glutaraldehyde solu-
tion and stained overnight at 37°C with 5 mM K3Fe[CN]6, 5 mM
K4Fe[CN]6, 2 mM MgCl2, 150 mM NaCl, 1 mg/ml X-gal in 40 mM
citric acid/Na2HPO4 (pH 6.0).
GST-RBD-Raf Pull-Down
The RAS binding domain (RBD) of RAF was coupled to GST, and
the pull-down experiment was performed as previously described
(de Rooij and Bos, 1997). In short, cell lysates were prepared by
lysing 4 × 106 cells in RIPA buffer (50 mM Tris [pH 8.0], 150 mM
NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, and protease inhibitors)
and incubated with precoupled GST-RBD for 30 min at 4°C. Beads
were collected by centrifugation, washed three times with RIPA
buffer, and resuspended in SDS loading buffer. Samples were ana-
lyzed by Western blot analysis.
RT-PCR and Q-PCR
cDNA was transcribed using SuperSCRIPT III (Invitrogen) following
the manfacturer’s instructions. PITX1 was PCR amplified using the
following primers: ATGGACGCCTTCAAGGGGGGC and TGCAACT
GCTGGCTTGTGAAG. For amplification of RASAL1, primers GCA
GGGAGGCGATTACAGCCGACCCCCGAG and GGGAAGCGAGTC
TTCTTGATGGTTGAGGTCTCC were used. For amplification of
ALG-2, primers ATGGCCGCCTACTCTTACCGC and GTTGTCCCG
GTCGTACGTGCG were used. Samples were taken after 29, 32, and
35 cycles and analyzed by gel electrophoresis and ethidium bro-
mide staining.
For Q-PCR, a SYBRgreen PCR master mix (Applied Biosystems)
was used, and the samples were amplified and analyzed by an ABI-
Prism 7000 sequence detection system (Applied Biosystems).
Luciferase Assay
HEK293 cells were cotransfected with either 1 g PITX1-GFP or
H2B-GFP in combination with either 0.5 g POMC-firefly-luc (Vooijs
et al., 2002) or a RASAL1-firefly-luc reporter construct and 1 ng
SV40-renilla. Forty-eight hours after transfection, cells were lysed
in 200 l passive lysis buffer (Promega). The luciferase assay was
performed according to the manufacturer’s protocol (Dual Lucifer-
ase system, Promega). The relative luciferase activity was calcu-
lated as the activity of the reporter constructs compared to the
renilla activity.
Chromatin Immunoprecipitation Assay
HEK293 cells were transfected with either PITX1-GFP or H2B-GFP.
After 48 hr, the cells were harvested and crosslinked with 1% form-
aldehyde at room temperature for 20 min. The ChIP assay was per-
formed as previously described, using 25 g genomic DNA for each
analysis. (Barre et al., 2005). Immunoprecipitation was performed
overnight at 4°C with a GFP-specific antibody or a cyclin D1 anti-
body as a control. After eluting twice with 1% SDS and 0.1 M
NaHCO3, the eluates were pooled and subjected to a phenol/chlo-
Cell
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